Chlamydia trachomatis is the causative agent of one of the most widespread bacterial sexually transmitted diseases in the world causing an estimated 92 million infections per years with over 11,000 infections last year in BC alone. With treatment failing to stem the spread of infection, a vaccine is widely acknowledged as the only way by which to prevent the suffering and significant infertility caused by C. trachomatis. It has been shown that four Chlamydia outer membrane proteins (PmpG, PmpE, PmpF and PmpH) are individually capable of eliciting protective immunity in the murine genital tract infection model against Chlamydia infection when formulated with a Th1 polarizing adjuvant. The project aims to accelerate the development and commercialization of a novel Chlamydia vaccine by completing murine studies prior to non-human primate and human trials. Efficacy, pathology and safety results from these experiments should inform the next steps, once the best delivery system has been established, be that individual proteins, a fusion protein or a native form as part of modified Chlamydia Outer Membrane Cmplex (COMC). It is hoped that the NIH (who supported earlier work) will provide the resources to carry out the next phase of work. At the same time, the process for filing a Food and Drug Administrator (FDA) Investigator New Drug (IND) submission, toxicology work and Good Manufacture Practice vaccine formulation will be ongoing.